Virtual Clinical Studies
We match patient profiles to avatar models in our “flybrary” or develop avatar models from patients you are recruiting on study. Matching in vivo models with patients recruited, enables the rapid testing and evaluation for patient enrolment, the best therapeutic interventions for patients, and support the repositioning and repurposing of previously approved drugs.
Use our matched patient genomic profiles and “flybrary” of models to investigate how to stratify patient or improve selection criteria for patient recruitment onto your clinical studies.
Determine the efficacy of your molecule(s) and/or in combination with 2,000 FDA approved drugs. Either participate in screening molecules in our regular cohort of patients as they are recruited each month to get early access to patient avatar models, utilise real patient avatars in our “flybrary” of models, or we can develop models for screening to your specification, or from your library of patient samples or genomic profiles.
Indication Selection and Profiling
Compare and contrast. Profile your molecule(s) in competition with each other or across multiple indications to discover the optimum molecule and indication to take into the clinical setting.
How does your lead molecule stack up against competitor molecules or existing standards of care? Our avatar models enable rapid and multidimensional screening of many drug combinations and options. A chance to differentiate your molecule(s) early in development.
Repurposing and Rescuing Pharmaceutical Drugs
About 80% of drug candidates fail in phase 2 trials because they don’t reach endpoints for efficacy. Of those drugs that get FDA approval, little is known about possible applications outside the narrow science of their original indication. MPT’s avatar platform enables the repurposing of marketed drugs or rescuing compounds which may have failed in clinical trials. If your drug has demonstrated a strong safety profile via a successful Phase I trial, the challenge is finding the right patient profile and/or FDA companion molecule for each patient that will improve efficacy. Multidimensional screening with patient avatars enables the rapid evaluation of multiple combinations to identify and characterise responders versus non-responders.